Three-Year Follow-up on Effects of Transdermal Estrogen
Authors: Edward G. Lufkin
Journal: Annals of Internal Medicine (1996)

Letters1 July 1996Three-Year Follow-up on Effects of Transdermal EstrogenEdward G. Lufkin, MD and Lawrence B. Riggs, MDEdward G. Lufkin, MDMayo Clinic and Foundation, Rochester, MN 55905Search for more papers by this author and Lawrence B. Riggs, MDMayo Clinic and Foundation, Rochester, MN 55905Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-125-1-199607010-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In a prospective clinical trial on the treatment of osteoporotic women with hormonal replacement therapy using 100 µg of transdermal estrogen per day plus progestin or placebo, we reported increases of 5.3% in lumbar spine bone mineral density and a significant decrease in vertebral fractures [1]. Hormone replacement therapy was continued for an additional 2 years in 29 of the 39 women in the treatment group, whereas the 39 women in the placebo group crossed over to receive hormone replacement therapy or withdrew from the study.Lumbar spine bone mineral density continued to increase during follow-up, reaching ...References1. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowica MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992; 117:1-9. Google Scholar2. Parfitt AM. Morphologic basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis [Editorial]. Miner Electrolyte Metab. 1980; 4:273-87. Google Scholar3. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990; 323:73-9. Google Scholar4. Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporos Int. 1991; 1:129-33. Google Scholar5. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fracture in postmenopausal osteoporosis. N Engl J Med. 1995; 333:1437-43. Google Scholar Author, Article, and Disclosure InformationAuthors: Edward G. Lufkin, MD; Lawrence B. Riggs, MDAffiliations: Mayo Clinic and Foundation, Rochester, MN 55905 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEffect of Teriparatide {rhPTH(1-34)} on BMD When Given to Postmenopausal Women Receiving Hormone Replacement TherapyEffect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal womenPerspectives on the Womenʼs Health Initiative Trial of Hormone Replacement TherapySex Steroids and the Construction and Conservation of the Adult SkeletonPharmacotherapy of osteoporosis in postmenopausal women: focus on safetyEstrogen and the SkeletonEndocrinology and AgingNew Approaches to Osteoporosis TherapeuticsA Multidisciplinary Renal Clinic for Corticosteroid-Induced Bone DiseaseTreatment Considerations in the Management of Age-Related OsteoporosisSouthwestern Internal Medicine ConferenceChanges in spine and radius bone density during long-term hormone replacementTreatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized TrialThe prevention and treatment of osteoporosisPharmaceuticals for Bone Disease Targeting the Osteoclast 1 July 1996Volume 125, Issue 1Page: 77KeywordsBoneBone densityClinical trial reportingEstrogensHormonal therapyHormone replacement therapyOsteocalcinOsteoporosisPhosphatasesSpine ePublished: 15 August 2000 Issue Published: 1 July 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...